Pooled Analysis of Pralatrexate Single-Agent Studies in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
In conclusion, these pooled analysis results further support using pralatrexate in patients with r/r PTCL. Prospective studies are needed to confirm the findings of subgroups analyses.PMID:38429077 | DOI:10.1182/bloodadvances.2023010441 (Source: Adv Data)
Source: Adv Data - March 1, 2024 Category: Epidemiology Authors: Owen A O'Connor Bor-Sheng Ko Ming-Chung Wang Dai Maruyama Yuqin Song Ee Min Yeoh Nick Manamley Kensei Tobinai Source Type: research
Cancers, Vol. 16, Pages 937: Evaluation of Quality of Life and Treatment Satisfaction in Newly Diagnosed Cutaneous T-Cell Lymphoma Patients
Conclusion: Despite that the newly diagnosed MF patients anticipate a positive treatment effect, few improvements in QoL and symptom reduction were found. These data can be used for adequate expectation management and provide a rationale for further evaluation of treatment regimens in these patients. (Source: Cancers)
Source: Cancers - February 26, 2024 Category: Cancer & Oncology Authors: Rosanne Ottevanger Sylvia van Beugen Juliette M. Kersten Andrea W. M. Evers Maarten H. Vermeer Rein Willemze Koen D. Quint Tags: Article Source Type: research
Failure of second challenge with Mogamulizumab in CCR4-positive cutaneous T-cell lymphoma
Br J Dermatol. 2024 Feb 23:ljae085. doi: 10.1093/bjd/ljae085. Online ahead of print.NO ABSTRACTPMID:38390970 | DOI:10.1093/bjd/ljae085 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - February 23, 2024 Category: Dermatology Authors: Romain Stammler Van Anh Ta Elisabeth Cohen Caroline Ram-Wolff Aliz ée Bozonnat Gilles Battesti Baptiste Louveau Samia Mourah Maxime Battistella H élène Moins-Teisserenc Ad èle de Masson Source Type: research
Failure of second challenge with Mogamulizumab in CCR4-positive cutaneous T-cell lymphoma
Br J Dermatol. 2024 Feb 23:ljae085. doi: 10.1093/bjd/ljae085. Online ahead of print.NO ABSTRACTPMID:38390970 | DOI:10.1093/bjd/ljae085 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - February 23, 2024 Category: Dermatology Authors: Romain Stammler Van Anh Ta Elisabeth Cohen Caroline Ram-Wolff Aliz ée Bozonnat Gilles Battesti Baptiste Louveau Samia Mourah Maxime Battistella H élène Moins-Teisserenc Ad èle de Masson Source Type: research
Experience with bexarotene to treat cutaneous T-cell lymphomas: a study of the Spanish Working Group of Cutaneous Lymphomas
CONCLUSIONS: Our study confirms bexarotene is a safe and effective therapy for the long-term treatment of CTCL.PMID:38395224 | DOI:10.1016/j.ad.2023.12.007 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - February 23, 2024 Category: Dermatology Authors: R Izu-Belloso I Gainza-Apraiz P Ortiz-Romero O Servitje-Bedate R Fern ández de Misa-Cabrera Y Pe ñate-Santana B Hernandez-Machin T Estrach-Panella M Llamas-Velasco J I Yanguas-Bayona M Morillo-Andujar E Acebo-Mari ñas S Perez-Gala J C Armario-Hita P Sa Source Type: research
Failure of second challenge with Mogamulizumab in CCR4-positive cutaneous T-cell lymphoma
Br J Dermatol. 2024 Feb 23:ljae085. doi: 10.1093/bjd/ljae085. Online ahead of print.NO ABSTRACTPMID:38390970 | DOI:10.1093/bjd/ljae085 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - February 23, 2024 Category: Dermatology Authors: Romain Stammler Van Anh Ta Elisabeth Cohen Caroline Ram-Wolff Aliz ée Bozonnat Gilles Battesti Baptiste Louveau Samia Mourah Maxime Battistella H élène Moins-Teisserenc Ad èle de Masson Source Type: research
Cancers, Vol. 16, Pages 861: JAK Inhibitors in Cutaneous T-Cell Lymphoma: Friend or Foe? A Systematic Review of the Published Literature
In conclusion, using JAK inhibitors for CTCL treatment seems promising with acceptable side effects, especially in patients with SPTCL. Some biomarkers, like pS6, showed an association with better responses. Caution should be taken when treating patients with an underlying autoimmune disease and prior immunosuppression. (Source: Cancers)
Source: Cancers - February 21, 2024 Category: Cancer & Oncology Authors: Seyed Mohammad Vahabi Saeed Bahramian Farzad Esmaeili Bardia Danaei Yasamin Kalantari Patrick Fazeli Sara Sadeghi Nima Hajizadeh Chalid Assaf Ifa Etesami Tags: Systematic Review Source Type: research
Toxicology, pharmacokinetics, and immunogenicity studies of CCR4-IL2 bispecific immunotoxin in rats and minipigs
In this study, we have performed non-GLP (Good Laboratory Practice) toxicology, pharmacokinetics, immunogenicity studies of CCR4-IL2-IT in both rats and minipigs. CCR4-IL2-IT demonstrated excellent safety profiles in both rats and minipigs. The maximum tolerated dose of CCR4-IL2-IT was determined as 0.4 mg/kg in both rats and minipigs. Complete blood count and chemistry analysis did not show significant difference for all measured parameters between the blood samples of pre-injection versus post-injection from the five-day toxicology studies of CCT4-IL2-IT in both rats and minipigs. Histology analysis did not show differen...
Source: European Journal of Pharmacology - February 17, 2024 Category: Drugs & Pharmacology Authors: Zhaohui Wang Rashmi Ramakrishna Yong Wang Yue Qiu Jihong Ma Danielle Mintzlaff Huiping Zhang Bing Li Benjamin Hammell M Scott Lucia Elizabeth Pomfret An-Jey Su Kia M Washington David W Mathes Zhirui Wang Source Type: research
Toxicology, pharmacokinetics, and immunogenicity studies of CCR4-IL2 bispecific immunotoxin in rats and minipigs
In this study, we have performed non-GLP (Good Laboratory Practice) toxicology, pharmacokinetics, immunogenicity studies of CCR4-IL2-IT in both rats and minipigs. CCR4-IL2-IT demonstrated excellent safety profiles in both rats and minipigs. The maximum tolerated dose of CCR4-IL2-IT was determined as 0.4 mg/kg in both rats and minipigs. Complete blood count and chemistry analysis did not show significant difference for all measured parameters between the blood samples of pre-injection versus post-injection from the five-day toxicology studies of CCT4-IL2-IT in both rats and minipigs. Histology analysis did not show differen...
Source: European Journal of Pharmacology - February 17, 2024 Category: Drugs & Pharmacology Authors: Zhaohui Wang Rashmi Ramakrishna Yong Wang Yue Qiu Jihong Ma Danielle Mintzlaff Huiping Zhang Bing Li Benjamin Hammell M Scott Lucia Elizabeth Pomfret An-Jey Su Kia M Washington David W Mathes Zhirui Wang Source Type: research
